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Abstract: Creatine (Cr) and phosphocreatine (PCr) are physiologically essential molecules for life,
given they serve as rapid and localized support of energy- and mechanical-dependent processes.
This evolutionary advantage is based on the action of creatine kinase (CK) isozymes that connect
places of ATP synthesis with sites of ATP consumption (the CK/PCr system). Supplementation with
creatine monohydrate (CrM) can enhance this system, resulting in well-known ergogenic effects and
potential health or therapeutic benefits. In spite of our vast knowledge about these molecules, no
integrative analysis of molecular mechanisms under a systems biology approach has been performed
to date; thus, we aimed to perform for the first time a convergent functional genomics analysis to
identify biological regulators mediating the effects of Cr supplementation in health and disease. A
total of 35 differentially expressed genes were analyzed. We identified top-ranked pathways and
biological processes mediating the effects of Cr supplementation. The impact of CrM on miRNAs
merits more research. We also cautiously suggest two dose–response functional pathways (kinaseand ubiquitin-driven) for the regulation of the Cr uptake. Our functional enrichment analysis, the
knowledge-based pathway reconstruction, and the identification of hub nodes provide meaningful
information for future studies. This work contributes to a better understanding of the well-reported
benefits of Cr in sports and its potential in health and disease conditions, although further clinical
research is needed to validate the proposed mechanisms.
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1. Introduction
Creatine (Cr), or alpha-methylguanidinoacetic acid (PubChem CID: 586), and its
phosphorylated form, phosphocreatine (PCr), are essential molecules for the optimal
functioning of tissues with high and fluctuating energy demands [1]. They provide an
evolutionary advantage via several creatine kinase (CK) isozymes that functionally connect
places of adenosine triphosphate (ATP) synthesis with sites of ATP consumption (the
CK/PCr system) [2]; therefore, Cr and PCr are physiologically essential for life through
a rapid and localized support of energy- and mechanical-dependent processes (i.e., cell
survival, growth, proliferation, differentiation, and migration or motility) [3,4]. For a recent
and comprehensive review of the Cr metabolism, please refer to [3].
The CK/PCr system can be enhanced through supplementation with creatine monohydrate (CrM), which is the most studied, safe, and effective nutritional supplement to
optimize physical performance [5–8], with potential benefits in health and disease [9–19].
It seems that the elevation of intracellular PCr concentration causes a greater capacity for
phosphagens to contribute to energy metabolism, while working to reduce the accumulation of Pi and H+ and improving Ca2+ handling as important mediators of fatigability
in young and older adults [20–23]. This has previously been reported in vivo and in vitro
after CrM supplementation [24–29]. Notwithstanding, a cellular environment rich in highenergy phosphates might also trigger downstream signaling pathways that are sensitive to
energy changes by activating secondary messengers and protein kinases [30,31]. In this
sense, several clinical trials [32–35] and research in animal models [36–38] have revealed
that CrM administration regulates the expression of particular genes or proteins using
low-throughput screening. In accordance with Kontou et al. [39], individual experiments
can only identify targeted regulators (based on prior knowledge), with limited comprehension of how the biological system works. As a result, data integration from multiple
experimental studies and public repositories is necessary to understand the function of biological entities (e.g., genes, proteins) and their expression patterns under certain conditions.
Additionally, ‘omics’ technologies in conjunction with the advance of bioinformatics tools
allow for data integration and the extraction of biologically relevant information, such as
identifying biomarkers and regulatory components within a network [40]. Consequently,
the use of a systems biology approach guarantees identification, at a systems scale, of the
molecular signatures of cellular processes, molecular interactions, and relevant metabolic
pathways present in the complex physiological responses or diseases with multi-factorial
underpinnings [41,42]. Among the different approaches, convergent functional genomics
(CFG) is an interesting methodological approach for the integrative analysis of molecular
mechanisms by combining multiple lines of genomic evidence from different species [43].
CFG takes advantage of the conserved nature of metabolic circuits between several species
(e.g., rodents and humans) [44] to provide relevant information about the structural and
functional changes within the cell when there is not enough available data or the experiments are difficult, if not impossible, to conduct in humans (e.g., those in brain tissue) [45].
While human data increase the clinical relevance (specificity), animal model data increase
the ability to identify the signal (sensitivity). Combined together, we enhance our ability
to distinguish signals from noise, even with limited cohorts and datasets [46]; therefore,
CFG is useful for identifying novel candidate genes and pathways for specific phenotypes [47–50] and compound-mediated gene regulation [51,52]. It is necessary to point
out the complementary features of low- and high-throughput analysis, given that subsequent validation of the identified metabolic hubs requires the high sensitivity, lower noise,
and reproducibility of low-throughput techniques (e.g., post-transcriptional regulation
assessment, targeted-molecules expression, protein–protein interactions) [53].
In the context of novel models of physiological regulation, the concept of allostasis
was developed. This highlights the importance of the anticipation of needs (such as the
timely provision of energy and adequate environmental conditions) for the functional
and structural stability of cells through adaptive changes [54]. Although efforts have
been made to integrate the different points of metabolic regulation to explain the positive
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effects of CrM supplementation on physical performance [55–57] and health or therapeutic
benefits [58–60], no systems biology analysis has been performed to date. Readers are
encouraged to refer to the comprehensive reviews in the Special Issue on “Creatine Supplementation for Health and Clinical Diseases” to learn more about the effects of CrM
supplementation [9]. The use of a systems biology approach might contribute to better
comprehension of the molecular, cellular, tissue, and systemic effects of CrM and its applications to health and disease; thus, the aim of this study was to perform for the first time a
CFG analysis to identify relevant pathways and biological processes mediating the effects
of Cr supplementation in health and disease. This secondary analysis of the available
data on differentially expressed genes after CrM administration in humans and mice will
provide meaningful information for future studies.
2. Methods
2.1. Functional Genomic Analysis
2.1.1. Search and Sources of Evidence
In order to collect the gene expression data, two public repositories (NCBI Gene
Expression Omnibus (GEO: http://www.ncbi.nlm.nih.gov/geo (accessed on 14 January
2021)) and the ArrayExpress Archive (https://www.ebi.ac.uk/arrayexpress/) (accessed
on 14 January 2021) were searched following the PRISMA statement guidelines [61] and
international recommendations [62]. The following Boolean algorithm was used in the
GEO repository: (“creatine”[MeSH Terms] OR creatine monohydrate[All Fields]) AND supplementation[All Fields], while the free term “creatine” was used in the ArrayExpress Archive.
Repositories were accessed on 14 January 2021, although an updated search was conducted prior to manuscript submission. We also contacted corresponding authors (e-mail
communication) to obtain missing raw data when no record was found in the repositories.
2.1.2. Eligibility Criteria
The inclusion of gene expression data for the CFG analysis was restricted to the
following: (1) original experimental studies that screened for genes differing between
Cr and controls; (2) raw data deposited in the NCBI GEO or the ArrayExpress Archive;
(3) expression data obtained from any tissue or cell; (4) human or mouse experimental
models. The search excluded data obtained from the combination of Cr with other compounds. Information was extracted from each identified record and reported in a table,
including the organism, reference, GEO accession number, sample type, numbers of cases
and controls, and platform.
2.1.3. Analysis of Differentially Expressed Genes and Convergence
The GEO2R web application [63] was used to identify differentially expressed (DE)
genes in the datasets for human and mouse models (freely available at http://www.ncbi.
nlm.nih.gov/geo/geo2r/, accessed on 18 January 2021). For the analysis with the GEO2R
tool, samples from Cr treatment were taken as the experimental group, while untreated
samples were taken as the control group. GEO2R provides the following summary statistics
as generated by ‘limma’, which performs the top table computation to extract a table of the
top-ranked genes, including the adjusted p-values and raw p-values; moderated t-statistics,
B-statistics, or log-odds that the gene is differentially expressed; the log2-fold changes
between pairs of experimental conditions; and moderated F-statistics (which combines
the t-statistics for all the pair-wise comparisons into an overall test of significance for that
gene) [64].
A CFG approach was used to identify a list of candidate genes with multiple lines
of evidence from humans and mouse models. After the GEO2R analysis, the gene names
were extracted from the differentially expressed genes based on the adjusted p-values
using the Benjamini–Hochberg method. An online tool developed by Bioinformatics
and Evolutionary Genomics at VIB/UGent (Gent, Belgium) (http://bioinformatics.psb.
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ugent.be/webtools/Venn) was used to identify convergence in the list of genes from these
datasets (accessed on 29 January 2021).
2.1.4. Functional Enrichment Analysis
Gene Ontology (GO) enrichment analysis of the list of genes from the convergent
analysis was performed with the gene set enrichment analysis tool for mammalian gene
sets from Enrichr, which is a comprehensive resource for curated gene sets that was
published in 2013 [65] (http://amp.pharm.mssm.edu/Enrichr, accessed on 12 May 2021).
An exploratory analysis with the DAVID tool (https://david.ncifcrf.gov/, accessed on 12
May 2021) showed similar results to top terms sorted by p-value ranking using the Enrichr
platform, an outcome that was somewhat expected given the use a scoring method similar
to both the hypergeometric test and Fisher’s exact test; however, the advantages of Enrichr
over other tools are its comprehensiveness, ease of use, interactive visualization of the
results, and the calculation of a combined score, which has been demonstrated to recover
more of the ‘correct’ terms compared with the other methods (e.g., the over-representation
analysis, the Jaccard distance, or the number of overlapping genes) [66]. Enrichr also
retrieves the computational predictions of interactions between the list of genes from
the convergent analysis and small non-coding microRNAs (known as miRNAs) using
the miRTarBase library [67], which contains experimentally validated miRNA–mRNA
interactions. We reported the categories ranked as statistically significant based on adjusted
p-values using an inherent z-score permutation background correction on Fisher’s exact
test. The bioinformatics tools were accessed from 20 February to 12 May 2021.
2.1.5. Upstream Regulatory Pathway Analysis
We utilized the differentially expressed genes from the CFG analysis to infer the
upstream regulatory networks using the computational pipeline of the eXpression2Kinases
(X2K) Web (freely available at https://amp.pharm.mssm.edu/X2K/, accessed on 12 May
2021) [68]. X2K Web is an enhanced algorithm that performs an enrichment analysis to
prioritize transcription factors that most likely regulate the observed changes in mRNA
expression (ChEA and PWM), which was previously validated by Chen et al. [42]. It then
utilizes known protein–protein interactions (PPIs) to connect the identified transcription
factors to form a subnetwork. Finally, kinase enrichment analysis (KEA) is performed
to prioritize protein kinases known to phosphorylate substrates within the subnetwork
of transcription factors and the intermediate proteins that connect them. Top kinases
and regulatory proteins (ranked by hypergeometric p-values, which indicate unusual
differential expression in the database) were contrasted to individual low-throughput
experimental reports available in the literature.
3. Findings
3.1. Selection of Gene Expression Datasets
After retrieving the records using the Boolean algorithm, we obtained 33 datasets from
the GEO database, 20 from the ArrayExpress Archive, and one from the hand searching
process in Google Scholar. The expression data for one study that assessed changes in
muscle transcriptome after Cr supplementation during knee immobilization in healthy
young men [69] was not published within a public repository (unsuccessful e-mail communication). After the assessment for inclusion criteria, only four records were suitable
for eligibility, although one study was excluded from the analysis because a treatment
combination with Cr, tacrine, and moclobemide was carried out. The overall procedure for
data extraction is shown in the PRISMA flow chart (Figure 1).
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Table 1. Datasets used in the convergent functional genomic analysis.

Organism Reference

Organism
Human

Human

Reference
[70]

[70]

Mouse

[71]

Mouse
Mouse

[72]
[71]

GEO
Number
GEO

Design

Creatine Control

Design
NumberExpression profiling of vastus lateralis

muscle in a randomized, placeboExpression profiling of vastus
controlled, crossover, double-blind
lateralis muscle in a randomized, 12
GSE7877
design in young, healthy,
non-obese
placebomen supplemented
with
CrM vs.
controlled, crossover,
GSE7877 placebo (dextrose) for ten days
double-blind design in young,
Analysis of brains
of C57Bl/6J
animals
healthy,
non-obese
men
GSE5140
fed a Cr-supplemented
forCrM
six vs. 6
supplementeddiet
with
months
placebo
(dextrose) for ten days
GSE42356

GSE5140

Analysis
of brains of C57Bl/6J
3T3 fibroblasts
overexpressing
CRT
3
fed a5mM
Cr-supplemented
wereanimals
treated with
CrM
diet for six months

Creatine
12

Platform

Control

Platform

Buck Institute_Homo
sapiens_25K_verC

Buck
Institute_Homo
sapiens_25K_verC
Affymetrix Mouse

12

12

7

63

Genome 430 2.0
Array
Illumina MouseWG-6
Affymetrix Mouse
v2.0 expression
7
Genome 430
beadchip
2.0 Array

3.2. Analysis of Differentially Expressed Genes

Mouse

[72]

Illumina
3T3 fibroblasts overexpressing
MouseWG-6 v2.0
After the analysis with the GEO2R tool, the differentially
expressed
GSE42356
3
3 genes were
CRT were treated with 5mM CrM
expression
selected using the adjusted p < 0.05 as the cut-off. Subsequently, these lists of genes were
beadchip

3.2. Analysis of Differentially Expressed Genes
After the analysis with the GEO2R tool, the differentially expressed genes were
selected using the adjusted p < 0.05 as the cut-off. Subsequently, these lists of genes were
filtered for duplicates and empty gene names to retrieve 112 genes from GSE5140 (Table S1)
and 11 genes from GSE42356 (Table S2). The available expression profile analyzed by
Safdar et al. [70] with 34 genes from GSE7877 was used for subsequent analysis (Table S3).
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that the
35 selected
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Table
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Table 2. Functional annotation and miRNA enrichment analysis of the list of genes from the convergent analysis.

Category

GO ID

Term

Adjusted

Table 2. Functional annotation and miRNA enrichment analysis of the list of genes from the convergent
analysis.
p-Value
Category

Biological Process

Biological Process

Cellular Component

GO:0030879
GO ID
GO:0043069
GO:0030879
GO:0045765
GO:0071542
GO:0043069
GO:0001934
GO:0045765
GO:0005664
GO:0005682
GO:0071542
GO:0031904
GO:0001934
GO:0046540

0.00538
0.01899
0.00538
0.03483
0.05505
0.01899
0.05505
0.03483
0.2386
0.2386
0.05505
0.2386
0.05505
0.2386

Adjusted p-Value

Nuclear origin of replication recognition
complex

0.2386

GO:0005682

U5 snRNP

0.2386

GO:0031904

Endosome lumen

0.2386

GO:0046540

U4/U6 x U5 tri-snRNP complex

0.2386

GO:0005637

Nuclear inner membrane

0.2386

GO:0005664

Cellular Component

Mammary gland development
Term
Negative regulation of programmed cell death
Mammary
gland
development
Regulation of angiogenesis
Negative
regulation
of programmed
cell
Dopaminergic
neuron
differentiation
Positive regulation ofdeath
protein phosphorylation
Regulation
of angiogenesis
Nuclear origin
of replication
recognition complex
U5
snRNP
Dopaminergic
neuron
differentiation
Endosome lumen
Positive regulation of protein
U4/U6 xphosphorylation
U5 tri-snRNP complex
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GO ID

Term
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GO:0035198

miRNA binding

0.05290
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0.05290

7 of 26

Polyubiquitin-modification-dependent
GO:0005637
Nuclear inner membrane
0.2386
GO:0031593
0.05290
protein binding
GO:0035198
miRNA binding
0.05290
GO:0001664
G-protein-coupled
0.05290
GO:0036002
Pre-mRNAreceptor
bindingbinding
0.05290
miRBase Accession
Adjusted
p-Value
GO:0048365
Rac Description
GTPase binding
0.05290
GO:0031593
Polyubiquitin-modification-dependent
protein
binding
0.05290
MIMAT0000416
Mature sequence Homo sapiens miR-1-3p
0.0942
GO:0001664
G-protein-coupled receptor binding
0.05290
MIMAT0000275
Mature sequence Homo sapiens miR-218-5p
0.1405
Adjusted
miRBase
Accession
Description
MIMAT0000447
Mature sequence
Homo sapiens miR-134-5p
0.1513
p-Value
MIMAT0022487
Mature sequence
sequence Homo
0.1961
MIMAT0000416
Mature
Homosapiens
sapiensmiR-5694
miR-1-3p
0.0942
MIMAT0000275
Mature
sequence
Homo sapiens
miR-218-5p
0.1405
Stem
loop sequence
Homo sapiens
MI0000542
0.2492
MIMAT0000447
Mature sequencemiR-320a
Homo sapiens miR-134-5p
0.1513
MIMAT0022487
Mature sequence Homo sapiens miR-5694
0.1961
MI0000542
Stem loop sequence Homo sapiens miR-320a
0.2492

3.5. Upstream Regulatory Pathway Analysis

3.5.
Upstream
Regulatory
Pathway
Analysis
The
upstream
pathway
analysis
resulted in the proto-oncogene c-Fos (FOS), specificity
upstream
pathway
analysis resulted
the proto-oncogene
c-Fosthe
(FOS),
protein The
1 (SP1),
nuclear
transcription
factor Yinsubunit
alpha (NFYA),
enhancer of
specificity
protein
1 (SP1),
nuclear
transcription
factor
subunit complex,
alpha (NFYA),
zeste
homolog
2 (EZH2)
and
suppressor
of zeste
12 Y
(SUZ12)
zinc the
finger MIZof zeste
homolog 2Myc
(EZH2)
and suppressorprotein
of zeste (MYC),
12 (SUZ12)
complex,
typeenhancer
containing
1 (ZMIZ1),
proto-oncogene
protein
maxzinc
(MAX, also
finger MIZ-type containing 1 (ZMIZ1), Myc proto-oncogene protein (MYC), protein max
known as Myc-associated factor X), and erythroid transcription factor (GATA1) as the top
(MAX, also known as Myc-associated factor X), and erythroid transcription factor
transcription
most likely
observed
in gene
expression
(GATA1) asfactors
the top that
transcription
factorsregulate
that mostthe
likely
regulate changes
the observed
changes
afterinCr
administration.
kinase enrichment
analysis
showed
thatshowed
mitogen-activated
gene
expression after Our
Cr administration.
Our kinase
enrichment
analysis
that
protein
kinase 14 (MAPK14,
also known
as p38),
kinases (CDKs), casein
mitogen-activated
protein kinase
14 (MAPK14,
alsocyclin-dependent
known as p38), cyclin-dependent
kinases
(CDKs),alpha
casein(CSNK2A1,
kinase II subunit
alpha (CSNK2A1,
known as CK2A1),
kinase
II subunit
also known
as CK2A1),also
extracellular
signal-regulated
extracellular
(ERKs), protein
kinaseN-terminal
B (Akt/PKB),kinases
and c-Jun
N- are the
kinases
(ERKs),signal-regulated
protein kinasekinases
B (Akt/PKB),
and c-Jun
(JNKs)
terminal kinases (JNKs) are the top signaling pathways that activate kinases known to
top signaling pathways that activate kinases known to phosphorylate substrates within
phosphorylate substrates within our subnetwork of transcription factors and intermediate
our proteins
subnetwork
of transcription factors and intermediate proteins (Figure 3).
(Figure 3).
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Figure 3. Upstream regulatory pathway analysis of the 35 selected differentially expressed genes: (A). transcription factor
enrichment analysis; (B) protein–protein interaction expansion; (C) kinase enrichment analysis; (D) eXpression2Kinases
network. Figures were obtained from the X2K Web (https://amp.pharm.mssm.edu/X2K/, accessed on 12 May 2021) after
running the upstream pathway analysis of the selected genes as the input gene list.
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4. Discussion
From a systems biology perspective, the analysis of interactions and characteristics
of the system’s components (e.g., molecular system bioenergetics, genome-wide geneexpression profiling, and pathway identification) facilitates the deciphering of the action
mechanisms of various system-level properties and biological functions [73]. The CFG
approach has been described as a Bayesian way of cross-validating biological findings while
reducing uncertainty. In addition, the bioinformatics enrichment of groups of converged
genes leads to insights into pathways and mechanisms that may be involved in different
phenotypes [74]. This methodology has been successfully utilized, even with limited size
cohorts and datasets, in the study of gene associations with chronic fatigue syndrome [50];
biomarker identification for suicidality [48], attention-deficit–hyperactivity disorder [49],
stress-related psychiatric disorders [75], and mood disorders [52]; and the discovery of
novel candidate genes and signaling pathways for epileptogenesis [47] and retinol or
retinoic acid exposure [51]. In order to understand the underlying biological processes and
mechanisms mediating the effects of Cr administration, we performed a CFG analysis on
differentially expressed genes in humans and mice for the first time. Under the allostasis
paradigm (that is, adaptation to changes through mechanisms that alter the set point of
metabolic or physiological variables) [76], the CK/PCr system should be seen as an essential
mechanism for life (cell survival, growth, proliferation, differentiation, and migration or
motility). We previously suggested that the CK/PCr system works as a dynamic biosensor
of chemomechanical energy transduction [3] with ‘concurrent reactions with exchange
motifs’ [77] that might account for the wide range of diseases after alterations in intracellular
Cr concentrations. In agreement with the established regulation of cellular allostasis
through a complex balance of subcellular energy production and cellular mechanics [78],
our CFG and enrichment analysis showed several biological regulators related to energy
metabolism (extra- and intramitochondrial pathways) and cytoskeletal machinery (motor
and cytolinker proteins). This makes the CK/PCr system a fractal model that can be used
to exemplify the cytoskeleton-mediated, energy-driven, mechanoadaptative processes of
the cells. This is the first time an integrative approach has been implemented to elucidate
how the enhanced Cr metabolism (via CrM administration) is directly involved in the
cellular adaptations through a complex balance of subcellular energy production and
cellular mechanics.
4.1. Biological Pathways Mediating Effects
The functional annotation of the 35 selected differentially expressed genes after CrM
administration showed that these are involved in anti-apoptotic processes, cell differentiation, and positive regulation of protein phosphorylation cascades. It must be noted that
these genes perform functions throughout the cell (nuclear origin of replication recognition
complex (nucleus), U5 snRNP (transcription complex), and endosome lumen (vesicles))
through either receptor activation and secondary messengers (G-protein-coupled receptor
binding, Rac GTPase binding, and polyubiquitin modification-dependent protein binding)
or direct regulation of de novo biosynthesis (miRNA binding and pre-mRNA binding)
(Table 2). After transcription factor enrichment analysis, the proteins that most likely
regulate the observed changes in gene expression after Cr administration are involved
in cell survival, apoptosis, proliferation, differentiation, migration, and the cytoskeletal
structure. To highlight this, among the top ranked transcription factors (Figure 3A) of our
analysis we found: (i) FOS is a G0/G1 switch regulatory protein that heterodimerizes with
members of the JUN family of transcription factors to form AP-1 complexes and regulate
signal transduction, cell proliferation, and differentiation [79]; (ii) SP1 was the first to be
cloned and characterized of the specificity protein–Krüppel-like factor (Sp/KLF) family of
transcription factors, which are involved in multitude of cellular pathways and processes
by regulating tissue- and developmental-stage-specific gene expression [80]; (iii) NFYA is
one of the three subunits of a highly conserved and ubiquitously expressed heterotrimeric
transcription factor that regulate gene expression at promoter regions [81]; (iv) EZH2 and
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SUZ12 are essential for the integrity of the polycomb group complexes, the expression
of which rises at the G1/S phase transition [82,83]; (v) ZMIZ1 regulates the activity of
various transcription factors, including the androgen receptor, Smad3/4, and p53 [84]; and
(vi) MYC is implicated in cell growth [85], proliferation, differentiation [86], and cellular
adhesion and migration [87,88], and may dimerize with MAX to bind DNA and exert its
effects [89].
The analysis of upstream regulatory signaling pathways resulted in MAPKs, CDKs,
CSNK2A1, and Akt/PKB being the most representative after Cr administration. Although
no clinical research has been conducted to study the changes in CSNK2A1 or CDK expression after Cr supplementation, one would expect a possible regulatory effect given that
both proteins play an essential role during cell cycle progression and differentiation [90,91].
It is interesting to note that CK and CSNK2A1 activities vary similarly during muscle cell
differentiation, with CSNK2A1 being dispensable for (i) the maintenance of the myogenic
identity, (ii) the expression of early myogenic markers and late muscle-specific gene expression, and (iii) the control of myoblast fusion [92]. CSNK2 has been reported to control
the Janus kinase–signal transducer and activator of transcription (JAK/STAT) signaling
pathway [93], which is the principal mechanism for a wide range of growth factors and
cytokines where other pathways such as MAPKs and PI3K/Akt are involved [94]. This
JAK/STAT pathway activation might regulate somatic growth via binding transcriptional
enhancers in the IGF1 locus [95]. In addition, CSNK2A and CDKs share a common target,
the integrator of neurotransmitters called dopamine- and cAMP-regulated phosphoprotein32 (DARPP-32) [96]. DARPP-32 interacts with β-adducin at the cytoskeleton to mediate
rapid environmental effects on neurons [97], which might explain its upregulation after Cr
treatment to promote differentiation and maturation of neurons [98]. Again, we highlight
the dynamic biosensor role of the CK/PCr system in this type of chemomechanical energy
transduction process. Recently, CSNK2A has been reported to be a critical element of the
Th17/Treg cell balance and differentiation [99], meaning more research is needed to unravel
the mechanisms that explain the effects of Cr on chromatin remodeling in immune cells.
Since immunity regulation goes beyond the scope of this review, please refer to [15] for a
recent comprehensive summary of the current findings and future directions in this regard.
The phosphorylation cascades of MAPKs are key components of extracellular signal
transduction, with important roles in cell survival, proliferation, and differentiation. The
signal begins at the activation of receptor tyrosine kinases (RTKs) and other transmembrane
receptors via guanine nucleotide exchange factors (GEFs, such as the son of sevenless [SOS])
that lead to the active form of the small G-proteins Ras [100]. After their activation, the Ras
variants interact with MAPK kinase kinases (MAPKKK, also called MAP3Ks or MEKKs,
with Raf being the most representative member) to activate MAPK kinase (MAPKK, also
known as MEK), then finally MAPKs through scaffold and adaptor proteins such as KSR,
JIP, and OSM [101]. There are three main MAPK families with different isoforms, namely
the ERKs, the JNKs, and the p38 MAPKs (p38 α/β/γ/δ) [102]. Besides the hormone
regulation of RTKs (e.g., growth hormone, IGF-1), the MAPK pathway may be activated
by energy-driven mechanosensing [103,104] and osmosensing [105] mechanisms. Alternatively, activation of the IGF-1 receptor may stimulate the PI3K/Akt/mTORC1 pathway,
which has a crucial role in protein synthesis via RPS6K and 4E-BP1 [106]. Our functional
annotation analysis indicated that G-protein-coupled receptor binding (p = 0.002921) and
Rac GTPase binding (a subgroup of the Ras superfamily of GTP hydrolases) (p = 0.003855)
are among the top molecular functions of the differentially expressed genes that change
after Cr administration. It is possible that the experimentally reported activation of MAPKs
after Cr administration might be due to mechano- and osmosensing mechanisms driven
by the optimization of the CK/PCr system. For instance, CrM supplementation for ten
days has resulted in the mRNA overexpression of SPHK1 (osmosensing gene) and various
MAPKs in healthy men [70] (Appendix A Figure A1).
Interestingly, the results of our kinase enrichment analysis and the identification of
hub nodes (downstream effectors of the MAPK and IGF-1/PI3K/Akt pathways) (Figure 3)
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are in high agreement with the available low-throughput, high-sensitivity experimental
in vitro and in vivo evidence after Cr administration, such as qRT-PCR, Western blotting, and electrophoretic mobility shift assay. Several human and animal studies have
shown that Cr brings higher growth hormone concentrations [107]; overexpression of
IGF-1 [34,36,108,109]; upregulation and higher activity of Akt/PKB [70,110,111]; downregulation of myostatin and increase in GASP-1 [35]; overexpression of p38α (also called
MAPK14) [69,112,113]; overexpression and higher activity of RPS6K and 4E-BP1 [37,38,114];
upregulation of myocyte enhancer factor isoforms [111,115]; overexpression of myogenic
regulatory factors, such as MyoD, Myogenin, Myf5, and MRF4/Myf6/Herculin [32,33,36];
and overexpression of myosin heavy chain (MHC) isoforms [116]. Remarkably, our kinase enrichment analysis (Figure 3C–D) showed high agreement with the protein kinase
content after CrM supplementation, as reported by Safdar et al. (Figure A1) [70]. All
aforementioned experimental evidence validates the power of the computational prediction of the multi-species convergent analysis, which highlights the need to include this
before performing low-throughput experimental analysis. It must be noted that many of
the signaling pathways that might be activated after Cr administration (Figure 4) follow
‘concurrent
reaction with exchange motifs’, which are characterized by the high
level of
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Figure 4. Bioinformatics- and knowledge-based pathway reconstruction after Cr supplementation. This is a representation
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of the cytoskeleton are not depicted for readability. We cautiously suggest two dose–response functional pathways for the
regulation of the Cr uptake: a kinase-driven mechanism as a result of the initial Cr-enriched environment, which is more
related to the anterograde trafficking via endolysosome-specific phosphoinositide compounds (1); and a ubiquitin-driven
mechanism that controls the excessive Cr uptake, which is more related to the retrograde trafficking via clathrindependent and clathrin-independent processes (2). Interlinking protein filaments of the cytoskeleton are represented with
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optimization of the cytoskeleton (e.g., Four-and-a-Half Lim 2 is an important mechanosensor that triggers hypertrophy
in response to strain and also docks key metabolic enzymes involved in the energy transduction process, such as MCK, adenylate kinase, and phosphofructokinase). Several subunits of the protein complexes and the architecture of the
cytoskeleton are not depicted for readability. We cautiously suggest two dose–response functional pathways for the
regulation of the Cr uptake: a kinase-driven mechanism as a result of the initial Cr-enriched environment, which is more
related to the anterograde trafficking via endolysosome-specific phosphoinositide compounds (1); and a ubiquitin-driven
mechanism that controls the excessive Cr uptake, which is more related to the retrograde trafficking via clathrin-dependent
and clathrin-independent processes (2). Interlinking protein filaments of the cytoskeleton are represented with lightercolored lines in the background. See the sections of the manuscript for rationale, citations, and more abbreviations.
Dashed arrows represent multiple steps. AMPK: AMP-activated protein kinase; CK: creatine kinase; GASP-1: growth
and differentiation factor (GDF)-associated serum protein-1; GDP: guanosine diphosphate; GH: growth hormone; GLUT:
glucose transporter; GRB2: growth factor receptor-bound protein 2; GTP: guanosine triphosphate; IGF-1: insulin-like
growth factor-1; LST8: target of rapamycin complex subunit LST8; MRFs: myogenic regulatory factors; Nedd4-2: E3
ubiquitin–protein ligase NEDD4-like; OSR1: oxidative-stress-responsive kinase 1; PDK1: phosphoinositide-dependent
kinase-1; PFK: phosphofructokinase; PI(3,5)P2 : phosphatidylinositol 3,5-bisphosphate; PIKfyve: 1-phosphatidylinositol
3-phosphate 5-kinase; PI3K: phosphoinositide 3-kinase; PIP3 : phosphatidylinositol (3,4,5)-trisphosphate; PK: pyruvate
kinase; SGK: serum- and glucocorticoid-regulated kinase; SPAK: SPS1-related proline–alanine-rich kinase; RACK1: receptor
for activated C kinase 1; RTK: receptor tyrosine kinases; TFs: transcription factors. Source: created by the authors (D.A.B.)
with BioRender—https://biorender.com/ (accessed on 10 May 2021).

4.2. Creatine and miRNAs
Interesting results were obtained from Enrichr using the miRTarBase data library
to analyze the miRNAs interactions. Regarding cancer, recent evidence has suggested
that Cr supplementation might have a carcinogenic effect [117]; nevertheless, contrary to
this hypothesis, the formation of carcinogenic heterocyclic amines is unrelated to CrM
supplementation [118], and even clinical research has demonstrated a potential anti-tumor
progression [119]. In fact, downregulation of the CK isozymes and low levels of PCr
and Cr are associated with sarcoma and adenocarcinoma progression [120]. Moreover,
Cr has been reported to enhance the anti-cancer effects of methylglyoxal in chemically
induced muscle cancerous cells in vitro and in sarcoma mouse cells in vivo [121]. In our
bioinformatics-assisted review of the Cr metabolism [3], we discussed the observed latency
towards reliance on glycolysis at high physical work rates after Cr administration, which
might explain the observed reduction in lactate accumulation (possibly via inhibition of
phosphofructokinase [122] and pyruvate kinase [123]) and the potential anti-tumor progression of Cr and its derivatives [124–126]. In this sense, the human muscle transcriptome
analysis performed by Safdar et al. [70] demonstrated that a 10-day CrM supplementation
period decreased the phosphofructokinase mRNA content by 21% versus placebo. For a
recent review on the role of Cr in T cell anti-tumor immunity and cancer immunotherapy,
please refer to Li and Yang [127].
Our enrichment analysis revealed for the first time that Cr administration might impact certain miRNAs that control cancer progression and muscle function. We are aware
that more experimental evidence is needed to the identify clinical effects, therapeutic
targets, and potential biomarkers in health and disease states, especially in certain cancer
phenotypes where a Cr-dependent tumor progression has been proposed based on preclinical data [128]. Table 3 briefly describes the functions of several of the top-ranked miRNAs
that were computationally predicted to interact with the list of selected differentially
expressed genes altered after CrM administration.
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Table 3. Information of predicted miRNAs interacting with the list of genes from the CFG analysis.
MicroRNA
miR-1-3p
miR-218-5p

miR-134-5p

miR-5694

miR-320a
miR-200b-3p
miR-126a-3p

miR-378a-3p

Relevant Information
Suppresses the proliferation of hepatocellular carcinoma [129] and
slows the proliferation and invasion of gastric [130] and lung
adenocarcinoma [131].
Significantly upregulated during myogenic differentiation after
activating the IGF-1 and MAPK/ERK pathways [132].
Lower levels are found in prostate cancer compared to benign
prostatic hyperplasia [133]. In addition, it might have
neuroprotective effects by regulating the miR-134-5p/CREB pathway
in both humans and mice [134].
Mediates downregulation of AF9 (a subunit of the super elongation
complex and associates with the histone methyltransferases) and
provides metastatic advantages in basal-like breast cancer cells [135].
Although associated with certain types of cancer, it has been shown
to inhibit the proliferation and progression of melanoma [136] and
gastric adenocarcinoma [137].
Higher expression is found in prostate cancer compared to benign
prostatic hyperplasia [133].
It targets low-density lipoprotein-receptor-related protein 1 and
blocks WNT signaling, which partially explain the anti-tumor effects
of curcumin [138].
Exhibits tumor-suppressive and anti-metastatic effects in esophageal
squamous cell carcinoma [139] and glioblastoma multiforme [140];
however, miR-378a might also have a pro-angiogenic effect on
myoblasts and control vascularization of skeletal muscle [141].

Since most of the identified miRNAs repress cancer progression, it would be appropriate to investigate the effects of CrM administration on these biological elements to evaluate
at which point Cr might regulate excessive proliferation. These post-transcriptional gene
regulators open a new field of research regarding the therapeutic role of CrM supplementation on health-related conditions. It needs to be noted that the osmosensing activation
of MAPK via Sphk1/S1P is related to several miRNAs [142], as well as the notion that
the effect of Cr on focal adhesion kinase [38,70] (Figure A1) might control muscle cell
differentiation through a small set of miRNAs that are connected to the focal adhesion
signaling during muscle regeneration, as was reported recently [143]. Further experimental
validation is warranted in the future.
4.3. The Regulation of the Creatine Transporter
In agreement with Santacruz et al. (2015), the elucidation for creatine transporter
(CRT, also known as SLC6A8) regulation merits further study given its importance to the
optimal function of several human tissues [144]. It needs to be noted that Cr belongs to a
set of seven putative systems biomarkers for Alzheimer’s disease, Parkinson’s disease, and
amyotrophic lateral sclerosis [145], which highlights its remarkable influence on neuron
survival and function. Since it is not able to increase itself to the same extent as skeletal
muscle, most of the research on enhancing Cr uptake using intermediate compounds (e.g.,
guanidinoacetate) or derivatives (e.g., Cr ethyl ester, dodecyl Cr ester, cyclocreatine, and Cr
gluconate) is focused on the brain [18] and the heart [146]. Additionally, even if intracellular
Cr levels increase after CrM (or Cr analogous) supplementation, the uptake is limited by
CRT downregulation due to mechanisms that are not fully understood. CrM supplementation has been shown to reduce the maximum rate of CRT activity (Vmax ) with no changes in
the CRT expression [144,147,148], reinforcing the hypothesis of endosomal internalization.
Based on the results of our CFG and enrichment analysis, we performed a pathway
reconstruction using well-characterized and experimentally validated PPIs to identify
the possible mechanistic progression for the trafficking regulation of the CRT after CrM
supplementation. By combining a knowledge-based approach [149] and the results of our
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upstream regulatory analysis to build the pathway, we obtained two dose–response and
complementary functional networks: (i) a kinase-driven mechanism as a result of the initial
Cr-enriched environment (more related to the anterograde trafficking); (ii) a ubiquitindriven mechanism that controls the excessive Cr uptake (more related to the retrograde
trafficking) (Figure 4). A third possible mechanism encompasses the initial upregulation
of the full-length CRT by splice variants (SLC6A8C and SLC6A8D), considering that our
functional annotation revealed that the differentially expressed genes perform a function
in the U5–snRNP complex, which is involved in the pre-mRNA splicing events; however,
this will not be further discussed because of the lack of experimental support beyond the
study by Ndika et al. [150].
The enhancement of the CK/PCr system (Cr-enriched environment) via CrM supplementation leads to the previously discussed activation of mechano- and energy-sensing
pathways, such as MAPKs and IGF-1/PI3K/Akt. The CRT function may be susceptible to
regulation by several kinases of these cascades [151]. Two-electrode voltage clamp recordings have revealed that mTOR [152], SGK1/3 [153], and 1-phosphatidylinositol 3-phosphate
5-kinase (PIKfyve) [154] enhance Cr uptake. It has been suggested that this process might
be mediated by the production of phosphatidylinositol-3,5-bisphosphate (PI(3,5)P2 ), which
is implicated in cytoskeleton rearrangement and cellular motility and provides spatial and
temporal control for membrane trafficking [155]. For example, GLUT-4 translocation is
regulated by PI(3,5)P2 concentrations, given that PIKfyve is localized in a subpopulation of
highly dynamic vesicles containing this transporter and may be activated by Akt/PKB after
triggering the insulin receptor pathway [156]. Additionally, SGK can phosphorylate the
E3 ubiquitin–protein ligase NEDD4-like (Nedd4-2), which reduces the ability of Nedd4-2
to interact with target proteins due to the interaction of the phosphorylated form with its
scaffolding protein 14-3-3 [157]. This positive feedforward mechanism has been reported in
the trafficking regulation of other membrane transporters [158,159]. Interestingly, Klotho
protein, a transmembrane protein determinant of aging and life span, upregulates the
activity of CRT by stabilizing the carrier protein in the cell membrane [160]. Klotho serves
as a powerful regulator of cellular transport across the plasma membrane [161] and is
associated with the activation of ERK 1/2 and SGK1 signaling cascades [162]. In recent
years, Klotho has been linked to glycolysis inhibition and anti-cancer activity [163], which
deserves more research due to its effect on Cr uptake. Further research is also needed to
understand the molecular processes that account for the increased CRT expression and Cr
uptake after activation of the estrogen-related receptor α [164].
As part of the hormetic dose–response, it is also plausible that the continuous increase
in Cr concentration activates cellular responses that negatively regulate Cr uptake via
possible ubiquitin-related mechanisms. Zervou et al. (2016) showed that very high Cr
concentrations (>160 nmol·mg−1 protein) might lead to impaired energy metabolism
in cardiomyocytes of transgenic mice overexpressing CRT, in what the authors defined
as a ‘substrate-rich but energy-poor heart’ [165]; thus, similar to other protein carriers,
downregulation of the CRT might result from nutrient sensitivity, energy sufficiency, and
osmotic changes [166]. Thioredoxin-interacting protein (Txnip), a member of a novel family
of proteins termed α-arrestin or arrestin-domain-containing proteins that possess homology
to β-arrestins [167], has been identified as the only gene upregulated after saturating cells
with Cr in vitro (Figure 2). This seems to be relevant in vivo, since higher mRNA (57.6%)
and protein (28.7%) levels of Txnip were found in animal models overexpressing CRT, while
Cr-deficient mouse hearts showed lower mRNA (39.71%) expression in comparison to
wild-type animals [72]. Thioredoxin (Txn1) is a small and ubiquitously expressed protein,
which in conjunction with thioredoxin reductase, reduces free radical oxygen species,
protein disulfides, and other oxidants [168]. The Txnip binds to Txn1 to exert critical
functions in terms of energy metabolism (e.g., increase redox stress, inhibit cellular glucose
uptake, among others) [169]. Notably, the arrestin domains are the crucial structural
elements in the metabolic functions of proteins such as Txnip [170], given that they operate
as multifaceted protein trafficking adaptors that serve as signaling scaffolds of multiple
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protein kinases. They bind to membrane cargo proteins and interact with the adaptor
protein complex 2, which is the second most abundant component of clathrin-coated
vesicles, in order to promote endocytic turnover of their cargos [171]. As the archetypal
β-arrestin, Tnxip has two major structural domains: the NH2 domain for protein–protein
interaction, with SH3 -binding proteins and MAP3Ks [172]; and the COOH domain, with
proline-rich motifs that not only bind to both adaptin and clathrin heavy chains but
also interact and recruit WW-domain-containing E3 ubiquitin ligases, such as Nedd4-2,
to ubiquitinate proteins and promote internalization to endosomes [173]. In addition,
α-arrestins are likely to utilize other mechanisms to mark cargo for internalization by
clathrin-independent endocytosis [174]. It must be noted that JNK1, a top-ranked protein
kinase from our enrichment analysis, may phosphorylate and activate Nedd4-2 [175,176].
Interestingly, upstream activators of JNK1 such as JAK2 [177], JAK3 [178], and PKC [179]
have been reported to be negative regulators of the CRT; therefore, endosomal trafficking
of CRT might be highly regulated by Cr concentration and energy sufficiency. Likewise,
regulation of GLUT proteins by Txnip depends on glucose and energy-sensing pathways,
taking into account that if the AMP/ATP ratio increases, AMPK becomes activated and
phosphorylates Txnip to induce its degradation. This results in the repression of GLUT
protein endocytosis and promotes glucose uptake to relieve energy stress [180]. Regarding
Cr uptake, contradictory findings have been found regarding the regulation of CRT by
AMPK [181,182], which deserves more research; the biologically conserved response to
the mechanical stress induced by altered osmolarity [166] might also contribute to the
control of Cr uptake (as a cellular hyperhydrating agent). Besides the kinase activity
and the possible ubiquitination of CRT via Txnip/Nedd4-2, the JNK is considered the
main mechanism for osmosensing signal transduction [183]. Furthermore, it has been
demonstrated that SPAK and OSR1 are negative regulators of the CRT [184]. These kinases
are part of the osmosensing WNK-SPAK/OSR1 pathway, considered the master regulator
of cation-chloride cotransporters [185], such as the CRT. This osmosensing regulation of
clathrin-mediated endocytosis is preserved among several species [186–189].
It is worth mentioning the successful strategies carried out in recent years to rescue
misfolded and endoplasmic-reticulum-trapped CRT variants with the use of pharmacochaperones such as the FDA-approved 4-phenylbutyrate [190]. Several mutations of
the CRT may result in transporter malfunction due to misfolding followed by impaired
expression or reduced trafficking to the plasmalemma surface. Conformational changes
of the CRT might trigger quality control mechanisms involving N-glycosylation (e.g., unfolded protein response) [191]. For a recent comprehensive review on this topic and novel
therapeutic strategies related to Cr deficiency syndrome, please refer to [192].
5. Limitations, Strengths, and Future Directions
This study should be interpreted in light of the following limitations and strengths:
(i) A very low number of ‘omics’ studies have evaluated the effects of CrM supplementation
in humans, meaning future (epi)genomics, transcriptomics, proteomics, and metabolomics
studies in this area are needed. Specifically, only one human dataset was deposited in
the repositories (GEO), showing again that more publicly available datasets are needed to
strengthen the current findings; however, the CFG approach has been highlighted for its
ability to distinguish signals from noise, even with limited cohorts and datasets [74,193].
(ii) The findings of the CFG, the bioinformatics enrichment analysis, as well as the conclusions from in vitro and in vivo animal models should be interpreted with caution, given
they might not fully reflect cellular changes in humans after CrM supplementation but
rather represent a mechanistic insight into cellular dynamics and proof-of-concept evidence to develop novel therapeutic strategies through the assessment of pharmacological
activators and inhibitors. (iii) Despite the limitations in the number of expression datasets,
the results obtained in the enrichment analysis (Enrichr and X2K) were contrasted and
supported by low-throughput, high-sensitivity experimental evidence that has identified
targeted genes and proteins related to the activated pathways after CrM supplementation
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in humans. However, experimental validation of candidate genes, protein, and miRNA
hubs from our analysis is warranted in the future. (iv) This study is a clear example of the
powerful features of the ‘omics’ high-throughput technologies and bioinformatics tools
and may represent a workflow for future studies that analyze emergent nutrients with
potential applications in sports and health or disease. In fact, understanding the interactions between system components and their regulatory aspects allow following a ‘biologic’
interpretation that is different and much more valuable than the common top-down or
bottom-up approaches.
Future studies on identifying biological regulators of CrM supplementation on health
and disease include: (i) the changes in miRNAs content (and other regulator non-coding
RNAs); for instance, the use of a small-interfering RNA against Txnip resulted in increased
Cr uptake [72], meaning further work will contribute to elucidating the mechanisms of the
Txnip–CRT interaction and its potential therapeutic use as a next-generation medicine [194];
(ii) the pharmacochaperones (e.g., 4-phenylbutyrate) and their safety and efficacy to treat
pathologies associated with the Cr deficiency syndrome; (iii) the implementation of a systems biology approach as a necessary and unavoidable process to study other metabolic networks of high complexity, such as the Cr metabolism; (iv) the integration of (epi)genomics,
transcriptomics, phosphoproteomics, and metabolomics analyses (multi-omic analysis).
In this sense, a very recent tool called Causal Oriented Search of Multi-Omic Space (COSMOS) [195] was developed to extract mechanistic insights in a more consistent and robust
manner. This opens up an exciting field of research with multiple applications in several
human conditions.
6. Conclusions
The CK/PCr system acts as a hub for chemomechanical energy transduction (i.e.,
dynamic biosensor) during the cellular allodynamic states. For the first time, a CFG with
enrichment analysis was performed to identify relevant pathways and biological processes
mediating the effects of Cr in health and disease. The results of our secondary analysis of
available gene expression data showed that several cytoskeleton-mediated, energy-driven,
mechanoadaptative processes possibly account for the wide range of effects and diseases
after alterations of intracellular Cr concentrations. Additionally, we cautiously suggest two
dose–response and complementary functional networks for the negative regulation of CRT
after the continuous increase in Cr concentration: (i) a kinase-driven mechanism responsible
for anterograde trafficking during the initial Cr-enriched environment; (ii) a ubiquitindriven mechanism that controls the excessive Cr uptake. In general, Cr metabolism
encompasses one of the most complex and dynamic networks, meaning further studies
will be expected to outline evidence detailing the positive roles of CrM supplementation
in other uncovered areas of health and disease. This work might contribute to a better
understanding of the well-reported benefits of Cr in sports and its potential in health and
disease, although more research is warranted to validate some of the proposed mechanisms.
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